Women’s Health Policy

This data note documents differences by sex in the work status of adult Medicaid enrollees ages 19-64 who were not receiving Supplemental Security Income (SSI) and were not dually eligible for Medicare in 2023, and highlights differences by parent status.

This factsheet discusses breast cancer screening and prevention services, and reviews the scope of private and public insurance coverage, as well as access to those services for women in the US.

This State and Federal Reproductive Rights Litigation tracker aggregates information about ongoing litigation regarding abortion bans and restrictions, FDA approval of Mifepristone (an abortion pill) and other federal regulations.

This KFF analysis demonstrates the impact the exclusion of Planned Parenthood from Medicaid and the Title X funding freeze may have on low-income and uninsured individuals who get their family planning care at Planned Parenthood.

This brief provides an overview of the most recent ACA case under review at the Supreme Court (Kennedy v. Braidwood Management) and discusses the implications of the potential rulings by the high court.

This data note looks at the Title X grantees and clinics affected by the Trump Administration’s recent funding freeze.

To improve the affordability of abortion services, many states have passed laws that require state-regulated plans to cover the full cost of abortion services for their enrollees. This data note documents the costs associated with abortion care in private plans. Also, KFF analyzes how out of pocket spending has been affected by state laws that require full coverage of abortion services.

This data note analyzes employer-sponsored insurance and Medicaid claims data to see how mifepristone and misoprostol—two drugs used in the medication abortion regimen—are prescribed for reasons other than abortion including management of miscarriages, abnormal bleeding or hemorrhage, as well as IUD insertions and other conditions.

In this brief, we describe Medina v. Planned Parenthood South Atlantic, the Medicaid policies underlying it, and potential implications for Medicaid beneficiaries’ access to reproductive health services.

In this brief, we explore avenues for expanding hormonal contraceptive care and supplies through pharmacies, as well as how and where pharmacies and pharmacists may be positioned to fill gaps in contraceptive care where there are few brick-and-mortar family planning providers, as well as the challenges in expanding these pathways.